* Leap Therapeutics Inc LPTX.OQ reported a quarterly
adjusted
loss of 10 cents per share for the quarter ended in December.
The mean expectation of five analysts for the quarter was for a
loss of 11 cents per share.
* Reported revenue was zero; analysts expected $1.20
million.
* Leap Therapeutics Inc's reported EPS for the quarter was a
loss
of 10 cents.
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* Leap Therapeutics Inc shares had fallen by 26.7% this
quarter.
* The company reported a quarterly loss of $12.1 million.
* Wall Street's median 12-month price target for Leap
Therapeutics
Inc is $2.50
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data
March 24 at 11:46 a.m. UTC. All figures in US dollars unless
otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2022 -0.11 -0.10 Beat
Sep. 30 2022 -0.12 -0.13 Missed
Jun. 30 2022 -0.10 -0.15 Missed
Mar. 31 2022 -0.10 -0.09 Beat